Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight Monday as the company presents new data at the Alzheimer’s Association International Conference in London. Wall Street weighed in on the stock last week.

Eli Lilly stock is trading flat. What’s next for LLY stock?

The AAIC PresentationEli Lilly is presenting 16 abstracts at the 2026 Alzheimer’s Association International Conference, running July 12-15 in London, with significant new data expected on its Alzheimer’s treatment Kisunla. The presentations could help clarify Kisunla’s competitive standing in a market where diagnosis bottlenecks, required scans, and monitoring requirements remain key hurdles to broader adoption.Kisunla at a GlanceAnalyst Consensus & Recent Actions The stock carries a Buy rating with an average price target of $1293.73. Recent analyst moves include:

B of A Securities: Buy (Raises Target to $1334.00) (July 10)

Truist Securities: Buy (Raises Target to $1370.00) (July 8)